Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Study to Evaluate the Efficacy and Safety of NBQ72S in Breast Cancer Patients With Leptomeningeal Metastases, With or Without Brain Parenchymal Metastases

NCT06810804 is registered in ClinicalTrials.gov with Nantong Bencao Quadriga Medical Technology Co. Ltd. as lead sponsor.

NCT NCT06810804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06810804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Study to Evaluate the Efficacy and Safety of NBQ72S in Breast Cancer Patients With Leptomeningeal Metastases, With or Without Brain Parenchymal Metastases
Lead sponsor
Nantong Bencao Quadriga Medical Technology Co. Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
April 22, 2025
Completion date
February 28, 2027
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer